ライフサイエンスコーパス: cyclin-dependent kinase inhibitor p21

1 st through transcriptional activation of the cyclin-dependent kinase inhibitor p21.

2 antial increase in the protein levels of the cyclin-dependent kinase inhibitor p21.

3 to induce transcription of genes such as the cyclin-dependent kinase inhibitor p21.

4 cells by neutralizing the activities of the cyclin-dependent kinase inhibitor p21.

5 rvival through Akt-mediated induction of the cyclin-dependent kinase inhibitor p21.

6 e progression, as well as with the universal cyclin-dependent kinase inhibitor p21.

7 l cycle associated with the induction of the cyclin-dependent kinase inhibitor p21.

8 t of the failure to induce expression of the cyclin-dependent kinase inhibitor p21.

9 in-2, AR-specific coactivator ARA70, and the cyclin-dependent kinase inhibitor p21.

10 cretin gene as well as the gene encoding the cyclin-dependent kinase inhibitor p21.

11 capable of transcriptionally activating the cyclin-dependent kinase inhibitor p21.

12 for p53 in the promoter of the gene for the cyclin-dependent kinase inhibitor p21.

13 with a p53-independent up-regulation of the cyclin-dependent kinase inhibitor p21.

14 excision repair, and PCNA interacts with the cyclin-dependent kinase inhibitor p21.

15 d resulted in decreased transcription of the cyclin-dependent kinase inhibitor p21.

16 ession of proarrest gene targets such as the cyclin-dependent kinase inhibitor p21.

17 and one of its transcriptional targets, the cyclin-dependent kinase inhibitor p21.

18 d DNA synthesis through the induction of the cyclin-dependent kinase inhibitor p21.

19 decreased transcriptional activation of the cyclin-dependent kinase inhibitor p21.

20 nd E, the transcription factor E2F1, and the cyclin-dependent kinase inhibitor p21.

21 led to a large increase in the levels of the cyclin-dependent kinase inhibitor p21.

22 genes while up-regulating expression of the cyclin-dependent kinase inhibitor p21.

23 aglandin A2 (PGA2) induces expression of the cyclin-dependent kinase inhibitor p21.

24 in part through decreasing expression of the cyclin dependent kinase inhibitor, p21.

25 regulator p53 and a protein p53 induces, the cyclin dependent kinase inhibitor, p21.

26 icative senescence are all influenced by the cyclin-dependent kinase inhibitor, p21.

27 pathways that culminate in expression of the cyclin-dependent kinase inhibitor, p21.

28 r levels of specific proteins, including the cyclin-dependent kinase inhibitor, p21.

29 nd cycle accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21.

30 associated with precocious induction of the cyclin-dependent kinase inhibitor, p21.

31 s to localize the CDK2-binding domain of the cyclin-dependent kinase inhibitor, p21.

32 rin are mediated by protein kinase B and the cyclin-dependent kinase inhibitor, p21.

33 ng p53-induced protein with death domain and cyclin-dependent kinase inhibitor, p21.

34 Increased levels of the cyclin:cyclin-dependent kinase inhibitor p21, a downstream effe

35 rt that cellular mRNAs encoding the cellular cyclin-dependent kinase inhibitor p21, a key inducer of

36 The cyclin-dependent kinase inhibitor p21, a major transcrip

37 The cyclin-dependent kinase inhibitor p21, a major transcrip

38 hat fine-tuning the expression levels of the cyclin-dependent kinase inhibitor p21, a p53 target gene

39 Transactivation of the cyclin-dependent-kinase inhibitor p21, a downstream targ

40 structs expressing Fas ligand (Ad-FasL), the cyclin-dependent kinase inhibitor p21 (Ad-p21), or beta-

41 f HIV-1 coreceptors and up-regulation of the cyclin-dependent kinase inhibitor p21 (also known as cip

42 ith strong and selective upregulation of the cyclin-dependent kinase inhibitor p21 (also known as cip

43 ncreased transcription and expression of the cyclin-dependent kinase inhibitor p21 and consequent cel

44 ciated with HER2-induced accumulation of the cyclin-dependent kinase inhibitor p21 and decrease in th

45 rrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expr

46 of PIAS1 induces p53-mediated expression of cyclin-dependent kinase inhibitor p21 and G(1) arrest of

47 ontained significantly reduced levels of the cyclin-dependent kinase inhibitor p21 and low levels of

48 this is correlated with an induction of the cyclin-dependent kinase inhibitor p21 and reduced cyclin

49 nally activated two of its target genes, the cyclin-dependent kinase inhibitor p21 and the mdm2 gene

50 arget genes, including those that encode the cyclin-dependent kinase inhibitor p21 and the proapoptot

51 GGTI-298 increases the levels of the cyclin-dependent kinase inhibitors p21 and p15 and had l

52 growth factor-beta (TGF-beta)can induce the cyclin-dependent kinase inhibitors p21 and p15 in a vari

53 matically, by up-regulation of mRNAs for the cyclin-dependent kinase inhibitors p21 and p15.

54 Furthermore, the G1 cyclin-dependent kinase inhibitors p21 and p16 also play

55 on of the Rb kinases, CDK4 and CDK6, and the cyclin-dependent kinase inhibitors p21 and p16 in senesc

56 Suppression involved an upregulation of cyclin-dependent kinase inhibitors p21 and p27 and the d

57 Strikingly, cyclin-dependent kinase inhibitors p21 and p27 underwent

58 le phase, and the expression of pAkt and the cyclin-dependent kinase inhibitors p21 and p27 was incre

59 This results in the accumulation of cyclin-dependent kinase inhibitors p21 and p27 with subs

60 for cdk2 and resistance to inhibition by the cyclin-dependent kinase inhibitors p21 and p27, (b) resi

61 ignificant increase in the expression of the cyclin-dependent kinase inhibitors p21 and p27, and a de

62 e/AKT signaling pathway, upregulation of the cyclin-dependent kinase inhibitors p21 and p27, antiprol

63 Progesterone induced the cyclin-dependent kinase inhibitors p21 and p27, thereby

64 , cyclin D1 expression, or the levels of the cyclin-dependent kinase inhibitors p21 and p27.

65 bited proliferation through induction of the cyclin-dependent kinase inhibitors p21 and p27.

66 fect was mediated through decreased level of cyclin-dependent kinase inhibitors p21 and p27.

67 o S phase by inducing the degradation of the cyclin-dependent kinase inhibitors p21 and p27.

68 -dependent increase in the expression of the cyclin-dependent kinase inhibitors p21 and p27; we also

69 ot alter the levels of p53 or the endogenous cyclin-dependent kinase inhibitors, p21 and p16.

70 f the tumor suppressor protein, p53, and the cyclin-dependent kinase inhibitors, p21 and p27, as well

71 on factor, Zta, can induce expression of the cyclin-dependent kinase inhibitors, p21 and p27, the tum

72 f the tumor suppressor protein, p53, and the cyclin-dependent kinase inhibitors, p21 and p27.

73 stronger than Ca(2+) in its induction of the cyclin-dependent kinase inhibitors, P21 and p27.

74 induction of endogenous p21(WAF1/CIP1) (the cyclin-dependent kinase inhibitor p21) and growth arrest

75 tion, stabilization of p53, induction of the cyclin-dependent kinase inhibitor p21, and homologous re

76 9, it inhibits BMP-mediated induction of the cyclin-dependent kinase inhibitor p21, and it reverses B

77 Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcription

78 ocodazole-treated adapted cells requires the cyclin-dependent kinase inhibitor p21, as p21-/- fibrobl

79 ed apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G

80 st cancer cells, increased expression of the cyclin-dependent kinase inhibitor p21 but had no effect

81 ally associated with induction of the potent cyclin-dependent kinase inhibitor p21, but not p27, and

82 OS) and by maintaining the expression of the cyclin-dependent kinase inhibitor p21(CDKN1A).

83 ultiple targets of the family, including the cyclin-dependent kinase inhibitor p21/CDKN1A.

84 r cells revealed increased expression of the cyclin-dependent kinase inhibitor, p21(CIP), independent

85 in the myogenic progenitor cell and that the cyclin-dependent kinase inhibitor, p21(CIP), may be a do

86 cancer cells led to increased levels of the cyclin-dependent kinase inhibitor p21 cip1/Waf1/Sdi1 and

87 tion of another p53 target gene encoding the cyclin dependent kinase inhibitor, p21(CIP1/Waf1).

88 rentiation of MLL-AF9 blasts, which requires cyclin-dependent kinase inhibitor p21(Cip1) (Cdkn1a) act

89 7-AAG blocked SAHA-mediated induction of the cyclin-dependent kinase inhibitor p21(CIP1) and resulted

90 The cyclin-dependent kinase inhibitor p21(Cip1) is up-regula

91 vely lower in HTSF compared to NADF, and the cyclin-dependent kinase inhibitor p21(cip1) is upregulat

92 The cyclin-dependent kinase inhibitor p21(Cip1) plays an imp

93 The cyclin-dependent kinase inhibitor p21(cip1) regulates ce

94 The cyclin-dependent kinase inhibitor p21(Cip1) regulates mu

95 ding protein CksHs2 were induced whereas the cyclin-dependent kinase inhibitor p21(Cip1) was represse

96 ypoxia-inducible factor (HIF) 1alpha and the cyclin-dependent kinase inhibitor p21(CIP1), a surprisin

97 p53 to transcriptionally induce mdm2 and the cyclin-dependent kinase inhibitor p21(Cip1), and to arre

98 s exhibit selective pX-induced expression of cyclin-dependent kinase inhibitor p21(Cip1), tumor suppr

99 t manner by increasing the expression of the cyclin-dependent kinase inhibitor p21(CIP1), which leads

100 kinase pathway and in down-regulation of the cyclin-dependent kinase inhibitor p21(Cip1), which resul

101 regulated genes, such as MDM2 itself and the cyclin-dependent kinase inhibitor p21(CIP1).

102 stoma suppressor protein pRb, as well as the cyclin-dependent kinase inhibitor p21(Cip1).

103 on of the transcription factor Msx-2 and the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) (p21).

104 ed marked elevation in the expression of the cyclin-dependent kinase inhibitor p21(cip1/waf1) accompa

105 t, differentiation-related activation of the cyclin-dependent kinase inhibitor p21(cip1/WAF1) gene is

106 The cyclin-dependent kinase inhibitor p21(Cip1/WAF1) has bee

107 K2AS treatment induced the expression of the cyclin-dependent kinase inhibitor p21(Cip1/Waf1) in pare

108 nstream-regulated gene 1 and upregulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) while d

109 The expression of the cyclin-dependent kinase inhibitor p21(Cip1/Waf1), caveol

110 its expression stimulates the expression of cyclin-dependent kinase inhibitor p21(CIP1/WAF1).

111 ited cell proliferation and up-regulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1).

112 hways are involved in the degradation of the cyclin-dependent kinase inhibitor p21(Cip1/WAF1).

113 ibits proliferation through induction of the cyclin-dependent kinase inhibitor p21(Cip1/WAF1/Sdi1), w

114 , causing a decrease in the induction of the cyclin-dependent kinase inhibitor, p21(Cip1), and an inc

115 as a strong repressor of the promoter of the cyclin-dependent kinase inhibitor, p21(CIP1), while RUNX

116 iptional repression of TLX target genes, the cyclin-dependent kinase inhibitor, p21(CIP1/WAF1)(p21),

117 ectopic expression of p16(INK4a) and another cyclin-dependent kinase inhibitor, p21(CIP1/WAF1), induc

118 was associated with increased binding of the cyclin-dependent kinase inhibitor, p21(Cip1/WAF1), to th

119 We investigated the role of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip

120 cyclin D2 and cyclin E, and induction of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip

121 n the targets of GR's cytostatic action, the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip

122 294002 resulted in the selective increase of cyclin-dependent kinase inhibitors p21(Cip1) or p27(Kip1

123 ve regulators of the cell cycle, such as the cyclin-dependent kinase inhibitors p21(Cip1), p27(Kip1),

124 has been proposed that the functions of the cyclin-dependent kinase inhibitors p21(Cip1/Waf1) and p2

125 egulation of cyclin D1, up-regulation of the cyclin-dependent kinase inhibitors, p21(cip1.) and p16(I

126 It was recently demonstrated that the cyclin-dependent kinase inhibitors, p21(Cip1/Waf1) (p21)

127 by hyperactivated NF-kappaB and mediated by cyclin-dependent kinase inhibitors, p21(CIP1/WAF1) and p

128 ggers a host senescence response mediated by cyclin-dependent kinase inhibitors: p21(CIP1/WAF1) (p21)

129 53 response, accompanied by induction of the cyclin-dependent kinase inhibitor p21/CIP1, which can be

130 phate (IP6) causes G(1) arrest and increases cyclin-dependent kinase inhibitors p21/Cip1 and p27/Kip1

131 However, overexpression of the cyclin-dependent kinase inhibitor p21 did not.

132 damage response signaling pathway involving cyclin-dependent kinase inhibitor p21 expression and het

133 53-induced transcriptional activation of the cyclin-dependent kinase inhibitor p21 in G1 cell cycle a

134 ed expression of the key p53 target gene and cyclin-dependent kinase inhibitor p21 in HCT116 cells, p

135 Skp2-mediated proteasomal degradation of the cyclin-dependent kinase inhibitor p21 in mammalian cells

136 ulating the basal level of expression of the cyclin-dependent kinase inhibitor p21 in the absence of

137 hat directly regulates the expression of the cyclin-dependent kinase inhibitor p21, independently of

138 d cellular proteins, including c-jun and the cyclin-dependent kinase inhibitor p21, indicating that d

139 We found that PCBP4 expression decreases cyclin-dependent kinase inhibitor p21 induction in respo

140 We have previously shown that the cyclin-dependent kinase inhibitor p21 inhibits the repli

141 Injection of the cdk (cyclin-dependent kinase) inhibitor p21 into one blastome

142 The cyclin-dependent kinase inhibitor p21 is an important pl

143 The cyclin-dependent kinase inhibitor p21 is an important tr

144 Here, we demonstrate that the cyclin-dependent kinase inhibitor p21 is both necessary

145 Expression of the cyclin-dependent kinase inhibitor p21 is highly induced

146 The cyclin-dependent kinase inhibitor p21 is induced in seve

147 usly, we demonstrated that expression of the cyclin-dependent kinase inhibitor p21 is reduced in syno

148 The p53-induced, cyclin-dependent kinase inhibitor p21 is strongly upregu

149 A key target of PC1, the cyclin-dependent kinase inhibitor p21, is also up-regula

150 The cyclin-dependent kinase inhibitor, p21, is known to be i

151 d at the promoters of the genes encoding the cyclin-dependent kinase inhibitor p21 or the transcripti

152 e to trigger an increase in the level of the cyclin-dependent kinase inhibitor p21 or to activate the

153 cyclin A expression, as co-expression of the cyclin-dependent kinase inhibitors p21 or p27, or a domi

154 xygenase-1, programmed cell death 4, and the cyclin-dependent kinase inhibitors p21, p27, and p57.

155 e inducible Src homology 2-containing genes, cyclin-dependent kinase inhibitors p21, p57, calmodulin

156 strongly suppress a phenotype caused by the cyclin-dependent kinase inhibitor p21, restoring S phase

157 dies indicate that myogenic induction of the cyclin-dependent kinase inhibitor p21 results in an inhi

158 an E3 ubiquitin ligase, CRL2(LRR1), for the cyclin-dependent kinase inhibitor p21 that specifically

159 ly that MDM2 promotes the degradation of the cyclin-dependent kinase inhibitor p21 through a ubiquiti

160 in D1, while it decreased the expressions of cyclin-dependent kinase inhibitor p21 (WAF-1/CIP1/MDA-6)

161 so find that p52 represses expression of the Cyclin-dependent kinase inhibitor p21(WAF/CIP1).

162 Expression of the cyclin-dependent kinase inhibitor, P21/Waf inhibits cell

163 Finally, the cyclin-dependent kinase inhibitor p21 WAF1 was induced i

164 hemical expression patterns of the prototype cyclin-dependent kinase inhibitor p21 WAF1/CIP1 and the

165 niposide (VM-26) both increase levels of the cyclin dependent kinase inhibitor, p21(waf1/cip1) and pr

166 HDACi induction of the cyclin-dependent kinase inhibitor p21(waf1) has been sho

167 Inducible p53-independent regulation of the cyclin-dependent kinase inhibitor p21(waf1) transcriptio

168 a), IFN regulatory factor-1 (IRF-1), and the cyclin-dependent kinase inhibitor p21(WAF1) was found in

169 t transcription, increased expression of the cyclin-dependent kinase inhibitor p21(Waf1), and accumul

170 s resulted in an increased production of the cyclin-dependent kinase inhibitor p21(WAF1), whereas no

171 hepatocytes via decreased expression of the cyclin-dependent kinase inhibitor p21(waf1).

172 The cyclin-dependent kinase inhibitor p21(WAF1,CIP1,SDI1) pl

173 rminus deficiency promotes expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (Cdkn1a

174 Ras promotes the accumulation of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (p21).

175 ll cycle arrest and apoptosis, including the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (p21).

176 liferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) (p21).

177 t transcription of both IkappaBalpha and the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and ind

178 Several genes including the cyclin-dependent kinase inhibitor p21(waf1/cip1) and the

179 While p53-regulated expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) appears

180 he rapid (within 30 minutes) increase of the cyclin-dependent kinase inhibitor p21(waf1/cip1) as well

181 cell cycle arrest through activation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene.

182 epithelial (HOSE) cells via induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) has bee

183 The cyclin-dependent kinase inhibitor p21(Waf1/Cip1) is a ma

184 tumorigenesis, targeted inactivation of the cyclin-dependent kinase inhibitor p21(WAF1/cip1) is high

185 In addition, expression of the cyclin-dependent kinase inhibitor p21(waf1/cip1) is requ

186 etermine whether p53 and the p53 target gene cyclin-dependent kinase inhibitor p21(WAF1/CIP1) were in

187 residues with the PCNA-binding domain of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), and al

188 9 degrees C show increased expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), charac

189 ent increased protein and mRNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1), increa

190 ntly increases transcription and activity of cyclin-dependent kinase inhibitor p21(WAF1/CIP1), leadin

191 on of manganese superoxide dismutase and the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), protei

192 ation, which results in up-regulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).

193 pathway, causing an accumulation of the G(1) cyclin-dependent kinase inhibitor p21(WAF1/CIP1).

194 ne protein p53 and elevation of the level of cyclin-dependent kinase inhibitor p21(WAF1/CIP1).

195 verexpress the tumour suppressor p53 and the cyclin-dependent kinase inhibitor p21(Waf1/Cip1).

196 increases the protein and RNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).

197 ith the p53 tumor suppressor protein and the cyclin-dependent kinase inhibitor p21(WAF1/Cip1).

198 the nitric oxide-dependent induction of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1).

199 Induction of cyclin-dependent kinase inhibitor p21(Waf1/Cip1/Sdi1) tr

200 The cyclin-dependent kinase inhibitor p21(WAF1/CIP1/SDI1/CAP

201 progression and increased expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIPl).

202 the ability to regulate transcription of the cyclin-dependent kinase inhibitor, p21(WAF1) (p21), one

203 with the p53-independent upregulation of the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1) (p21).

204 th a homozygous deletion of the gene for the cyclin-dependent kinase inhibitor, p21(WAF1/CIP1), do no

205 ation of p27 than by inactivation of another cyclin-dependent kinase inhibitor, p21(WAF1/cip1), the n

206 r senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1).

207 Among these changes was induction of the cyclin-dependent kinase inhibitor, p21(WAF1/cip1).

208 density-arrested cells of high levels of the cyclin-dependent kinase inhibitors p21(WAF1) and p27(KIP

209 on of G(1)-S-phase regulators, including the cyclin-dependent kinase inhibitors p21(waf1) and p27(kip

210 retinoblastoma protein and induction of the cyclin-dependent kinase inhibitors p21(waf1/cip1) and p2

211 t at the G(1)-S checkpoint, and induction of cyclin-dependent kinase inhibitors p21(waf1/cip1) and p2

212 In this study, we investigated the role of cyclin-dependent kinase inhibitors, p21(WAF1/cip1) (p21)

213 tein p53 and concurrent up-regulation of the cyclin-dependent kinase-inhibitor p21(WAF1/CIP1).

214 The cyclin-dependent kinase inhibitor p21((WAF1/CIP1)) inhib

215 he mechanism appeared to involve neither the cyclin-dependent kinase inhibitor, p21((waf1/cip1)) nor

216 ngs clearly demonstrate the up-regulation of cyclin-dependent kinase inhibitors p21((Waf1/Cip1)) and

217 xpression of p53 at 32 degrees C induced the cyclin-dependent kinase inhibitor p21/WAF1 and arrested

218 Here, we report that the cyclin-dependent kinase inhibitor p21/waf1 is overexpres

219 ess wild-type or mutant forms of p53, or the cyclin-dependent kinase inhibitor p21/WAF1, under a tetr

220 Expression of the cyclin-dependent kinase inhibitor p21/WAF1/Cip1 is induc

221 endent on increased expression of the cyclin/cyclin-dependent kinase inhibitor p21/WAF1/CIP1.

222 ntrol of proliferation and expression of the cyclin-dependent kinase inhibitor p21(WAFI/CIP1) seen in

223 These studies revealed that loss of the cyclin-dependent kinase inhibitor p21 was associated wit

224 sed expression of proapoptotic genes and the cyclin-dependent kinase inhibitor p21 was seen.

225 Levels of the cyclin-dependent kinase inhibitor, p21, were increased i

226 m-2; present throughout the cell cycle), and cyclin-dependent kinase inhibitor p21, which inhibits G

227 evels of bone morphogenetic proteins and the cyclin-dependent kinase inhibitor p21, which might contr